Zemcelpro® (UM171 Cell Therapy) receives EC authorization as the first and only cell therapy for blood cancer patients without access to suitable donor cells

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

ExCellThera-auth-UK

More Like This

PR Newswire associated0

Zemcelpro® (UM171 Cell Therapy) receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells

Zemcelpro® (UM171 Cell Therapy) licensing and supply agreements announced for Canada

PR Newswire associated0

Zemcelpro® (dorocubicel) receives NUB Status 1 in Germany

PR Newswire associated0

Zemcelpro® (dorocubicel) Positive Results in High- and Very High-Risk Blood Cancers to be Reported at the EBMT 2026 Annual Meeting

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

PR Newswire associated0

THERAKOS™ CELLEX™ Photopheresis System Receives CE Certificate Under the European Union Medical Device Regulation (EU MDR)

PR Newswire associated0

EUROPEAN COMMISSION APPROVES BLINCYTO® IN PHILADELPHIA CHROMOSOME-NEGATIVE CD19-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN THE CONSOLIDATION PHASE

Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars